Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. - Wikidata - wikimedia - TriplyDB

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

http://www.wikidata.org/entity/Q36729822

about

Stability engineering of the human antibody repertoire Improving biophysical properties of a bispecific antibody scaffold to aid developability Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development Opening the door to innovation Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange.Complement is activated by IgG hexamers assembled at the cell surface.The development of bispecific antibodies and their applications in tumor immune escape.Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis.Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing β-Glucan and MP65 Determinants in Candida Species.A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.Computationally Designed Bispecific Antibodies using Negative State Repertoires.Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.Synergistic Neutralization of Pertussis Toxin by a Bispecific Antibody In Vitro and In Vivo Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.Clinical pharmacology of bispecific antibody constructs.Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Bispecific antibodies for viral immunotherapy.Acute myeloid leukemia targets for bispecific antibodies.Current progress in innovative engineered antibodies.Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.

P2860

Q26859495-08D9A247-F309-454E-B313-DB747E046E92 Q27679445-B6B72558-1C5C-4563-AA82-5A7F3D9FB4DD Q28068946-4DA20115-599F-4B95-AEEA-971E39BB95E6 Q28072319-89D6E44B-3F13-4D2E-93F0-6F36E1B7D4C9 Q28082880-20260098-8B03-422A-BB5E-D099B45C24B2 Q28655591-BF12FA6C-7A13-49F3-AC96-F5D890EACA1B Q30357905-49386210-3AD4-4F26-A9B4-14D36E5AC278 Q30409381-09AC3366-0F48-424F-953F-BAD95C18B84A Q33630292-BAFB1D6C-C69A-4C34-9FDB-54560CF15227 Q33681420-6CD2B210-BDF4-47FD-9285-AB67C046A5CC Q33740334-774AD485-52D1-40CB-9B1C-E0B78B5E252F Q34539842-6BDA3CD8-E46F-4862-A34F-879F3B13CF4C Q34550963-9F6B36DF-0EC4-488F-9BDB-24198E2D73C4 Q34601167-490D2242-C0DA-4F1B-9EE9-70C0BD0CC07E Q34643044-518CF584-7BF6-4817-BDC5-884E9C3FF00F Q35052025-1762C43B-1A49-47D5-8C93-EDCFDA9B2CFE Q35119802-58DCC4A1-67BA-4BBC-8C2D-E8E574B56A36 Q35126618-134BCB92-6082-4BB5-854D-7F2E599EAACC Q35199371-21A1D9F6-AC66-4942-8892-6C1D8B716C06 Q35918232-26B1BB55-A91C-4EEA-B045-6F65B67D0843 Q36216092-D0801A65-5486-462E-A1EA-CDDFCF065F99 Q36334359-D6D59ED9-DE40-47D3-8F7A-140F7F5FC495 Q36899812-4B30A2BF-7829-4C1F-83B5-619AE02882EF Q37168393-7DDCD112-B573-49B9-BAEE-252CB1504D5B Q37287006-294AE57B-00DE-4889-98FF-C5A2417340A0 Q37396968-5E126B54-619C-4578-8746-88055A8EEDDB Q37496563-BEFCBF6A-D023-4A21-AD79-8B1A9A54C73B Q37496596-06D13704-CEC9-4A45-8948-FD21186821E6 Q37589825-5D3C4F3B-C6C3-416B-AF96-63F315FAD070 Q37593702-CCB5407C-C8CC-4867-9E7B-1F9F5C16032B Q37631316-C0B72225-A199-4262-86E7-24DEDF6CD632 Q38364459-2EBD671D-DD08-4648-B32C-8812063A9FBC Q38722574-BF5C6B16-A048-48AF-8731-56FFAA398A4F Q38790644-3A9B0859-0AC3-4E60-BE38-E7CF2C0599C0 Q38844694-5900877C-4563-4670-82BE-6EC0A96B058D Q38861238-A3E79C43-78A9-4F75-9834-6038B75E4319 Q38992408-6CC7FAA1-76F3-4A75-9CBF-F2D6A5DF3E11 Q39117761-87AC9876-786B-4ABB-8289-8F7BDDC95A9D Q40077818-B21A0215-C7CE-4F5D-B661-AD0A2BF1D28C Q41489391-658164DD-7F30-4C1B-B4BA-2DA4C194B6C3

P2860

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

http://www.wikidata.org/entity/Q36729822

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

@ast

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

@en

type

label

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

@ast

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

@en

prefLabel

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

@ast

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

@en

P1433

Q36729822-973067A4-DDE3-497D-8FFD-8CBF19114F7C

P1476

Q36729822-54E581B4-CE1A-4A2C-9EE0-71379B5F21B5

P2093

Q36729822-0F3D6671-4178-4040-9CB3-036D5F22BD3D

Q36729822-120F5374-CF0E-4392-91B6-1F741C73169A

Q36729822-3645E3B0-8C19-44BE-A2E8-E589B32F1428

Q36729822-42F48528-28FD-4C28-91C6-8CA16794B89D

Q36729822-5FB180FF-AAF4-4349-97AE-A8918FE4D0D4

Q36729822-72296925-7646-419D-A204-F8E08BB67D70

Q36729822-7CEE0BB1-F752-414E-BFAB-57210F14510B

Q36729822-C0DE0154-E89E-42F0-9C01-C33554316097

Q36729822-E7C9784B-4F83-405B-A399-17DAA43C1B2E

Q36729822-F9BA9A93-00A5-4A2C-BDF9-AF8589AE1918

P2860

Q36729822-05E157C2-96AD-49AE-87F4-0120809C2A9A

Q36729822-1564C997-EC4D-46B7-B757-AB235E5EFEE2

Q36729822-2344B1EF-969F-4152-9CE9-B793D6D38E0C

Q36729822-24C6849C-E107-487B-AF87-02FA8ECCE9E6

Q36729822-2B2B7CE2-5B6D-4859-BE73-A2156F68EE16

Q36729822-2EAC6962-13F9-4D53-9FB4-EFF8DC9E330C

Q36729822-2F9E6FF5-0D6E-4294-B30A-BC6D5E9B0EB3

Q36729822-32DB69AE-1440-4B8A-BAB0-06E6ADC09FDF

Q36729822-37ED699B-8CA3-4F74-BBB4-1BD593483D39

Q36729822-40628F12-B1BA-45D5-86BB-DD1C81FE0CD1

P304

Q36729822-A9575897-F9D9-49DB-8308-1A206BB8C3C8

P31

Q36729822-A44D2F3F-DB47-4316-B64C-650A7336ABE0

P356

Q36729822-FED3B96C-FE4B-4FF1-B5FB-F3D3BAD6954B

P407

Q36729822-DF339D83-5068-42B4-83D1-DF90A2BFF611

P433

Q36729822-38122A30-DDCC-4191-98D7-526F5EF1E763

P478

Q36729822-6E6A90EC-ADAC-4002-A6A5-B5B253BFAD7A

P50

Q36729822-BE0A8BDA-F687-4CCC-A6E4-47D1254BE512

Q36729822-D2A1395E-537B-4F97-B6E1-E476B29A42B4

Q36729822-E7978E0C-9D48-48E8-B889-17AA5D33AF9D

P577

Q36729822-A7245383-7893-4D6F-A7E4-C144B527E836

P5875

Q36729822-C7BCD147-24BB-495C-867A-1BF36A87DEAE

P698

Q36729822-ADF2E82D-61A9-448B-B6DC-7172B721764F

P932

Q36729822-17777A37-A04F-45B4-B5A2-F7927E53EA3B

P356

PNAS.1220145110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

@en

P2093

Amitava Kundu

http://www.w3.org/2001/XMLSchema#string

Ewald T J van den Bremer

http://www.w3.org/2001/XMLSchema#string

Jan G J van de Winkel

http://www.w3.org/2001/XMLSchema#string

Janine Schuurman

http://www.w3.org/2001/XMLSchema#string

Joost Neijssen

http://www.w3.org/2001/XMLSchema#string

Joyce I Meesters

http://www.w3.org/2001/XMLSchema#string

Kristin Strumane

http://www.w3.org/2001/XMLSchema#string

Michael J Gramer

http://www.w3.org/2001/XMLSchema#string

Muriel D van Kampen

http://www.w3.org/2001/XMLSchema#string

Patrick H C van Berkel

http://www.w3.org/2001/XMLSchema#string

P2860

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Bispecific T-cell engaging antibodies for cancer therapy

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

An efficient route to human bispecific IgG.

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.

Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

P304

5145-5150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1220145110

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Paul Whi Parren

P577

2013-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235906520

http://www.w3.org/2001/XMLSchema#string

P698

23479652

http://www.w3.org/2001/XMLSchema#string

P932

3612680

http://www.w3.org/2001/XMLSchema#string